Logo image
Inflammatory Markers and Risk of Cerebrovascular Events in Patients Initiating Dialysis
Journal article   Peer reviewed

Inflammatory Markers and Risk of Cerebrovascular Events in Patients Initiating Dialysis

Stephen M. Sozio, Josef Coresh, Bernard C. Jaar, Nancy E. Fink, Laura C. Plantinga, Paige A. Armstrong, J. Craig Longenecker, A. Richey Sharrett, Neil R. Powe and Rulan S. Parekh
Clinical journal of the American Society of Nephrology, v 6(6), pp 1292-1300
01 Jun 2011
PMID: 21551022
url
https://doi.org/10.2215/CJN.08350910View
Published, Version of Record (VoR) Restricted

Abstract

Life Sciences & Biomedicine Science & Technology Urology & Nephrology
Background and objectives Stroke remains a leading cause of morbidity and mortality for patients on dialysis; however, its risk factors in this population and measures to prevent it are not well understood. Design, setting, participants, & measurements We investigated whether inflammation was associated with cerebrovascular events in a national US cohort of 1041 incident dialysis patients enrolled from October 1995 to June 1998 and followed until January 31, 2004. Incident cerebrovascular events were defined as nonfatal (hospitalized stroke, carotid endarterectomy) and fatal (stroke death) events after dialysis initiation. With Cox proportional hazards regression analysis accounting for the competing risk of nonstroke death, we assessed the independent event risk associated with baseline levels of multiple inflammatory markers (high-sensitivity C-reactive protein [hsCRP], interleukin-6 (IL-6), matrix metalloproteinase-3 [MMP-3], and P-selectin) and hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) use, which may have pleiotropic inflammatory effects. Results 165 patients experienced a cerebrovascular event during 3548 person-years of follow-up; overall incidence rate was 4.9/100 person-years. None of the inflammatory markers were associated with cerebrovascular event risk (adjusted hazard ratios [HRs] per log unit [95% confidence interval]: hsCRP, 0.97 [0.85 to 1.11]; IL-6, 1.04 [0.85 to 1.26]; MMP-3, 1.02 [0.70 to 1.48]; P-selectin, 0.98 [0.57 to 1.68]). Statin use was also not associated with significant risk of events in unadjusted (HR 1.07 [0.69 to 1.681) or propensity-score adjusted analyses (HR 0.98 [0.61 to 1.56]). Conclusions In conclusion, neither inflammatory markers nor statin use was associated with risk of cerebrovascular events. Further studies are needed to understand the pathophysiology and prevention of stroke in patients on dialysis. Clin J Am Soc Nephrol 6: 1292-1300, 2011. doi: 10.2215/CJN.08350910

Metrics

4 Record Views
7 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Urology & Nephrology
Logo image